Use case · "I'm a VC. I want to challenge an expansion plan."
For investors: how to challenge a portfolio company's international plan before the round closes
For VCs, angels and family offices with a wellness or preventive health company raising on an international roadmap. A way to test the plan with data rather than with questions.
The limit of due diligence on expansion
Diligence on an international roadmap usually means three things: reading the market-size figures, calling a few experts in the target country, and asking the founder hard questions. All useful, all indirect. None of them puts the product in front of users in the target market and watches what happens. The plan is challenged with opinions, and the founder answers with opinions, and the round closes on whoever argued best.
There is a more direct instrument: run the market test before the term sheet, or make it a condition of the first tranche. Eight weeks of real usage in the target country turns "we believe Germany is next" into a number both sides can read.
Three ways investors use a market test
- Pre-term-sheet. A single-country test on the roadmap's first market, commissioned during diligence. Cost is small against the round size; the result shapes valuation and milestones.
- As a tranche condition. "Second tranche on a go reading in country X." It aligns the founder and the fund on the same evidence, and it replaces a vague milestone with a dated one.
- Portfolio-wide. Several companies in the portfolio weighing the same region. The same scorecard across companies gives the fund a comparative view no single founder has.
What the test produces for an investor
The same report the founder receives, written to be read by people outside the company: the panel's make-up (never identities), usage over eight weeks against the home benchmark, structured feedback, and a go / adjust / stop reading with reasons. For a multi-country comparison, a ranked deployment order. It is sourced, dated and reproducible, which is more than most expansion slides can claim.
Who commissions it, who pays
Either side can. In practice the company usually commissions the test and shares the report, because the founder wants the data as much as the investor. Where the investor commissions it, the founder is involved in scoping from day one: a test run against a founder produces a defensive founder and a worse test. Independence comes from the method and the pre-agreed threshold, not from excluding the company.
What this is not
It is not a market study (that measures the market, not the product), not a user research panel (one session of opinions), and not a clinical trial (medical safety and efficacy under regulatory supervision). It is a retention and fit test with real users in the target country, over enough weeks to see habit. For wellness and preventive health products, that is the evidence that is usually missing.
A portfolio company raising on an international plan?
Book a 30-minute call. We'll tell you what a test could show before the round closes, and what it can't.
Questions investors ask
Is the test independent if the company scopes it?
The threshold for a go is written in the one-page plan and signed before the test starts, by both the company and, if you wish, the fund. The result is read against that threshold. That is what makes it independent, not who signed the invoice.
How confidential is the report?
The report belongs to whoever commissioned it and is shared under the terms you set. Tester identities are never in it; usage data is pseudonymised from day one.
Does it work for later-stage companies?
Yes. Series B and C companies usually come with a country team and use the comparison or the product × market matrix format rather than a single-country go / no-go. The method is the same; the question is more specific.